Halozyme Therapeutics Inc. (NASDAQ: HALO) Increases 24.82% Over A Month, But Analysts Still See Upside Potential

Halozyme Therapeutics Inc. (NASDAQ:HALO) currently has a daily average trading volume of 962.45K but it saw 4597834 shares traded in last market. With a market cap of 6.55B USD, the company’s current market price of $51.44 came rising about 12.68 while comparing to the previous closing price of $45.65. In past 52 weeks, the stock remained buoying in the range of price level as high as $46.16 and as low as $32.78.

Taking a look at 20-day trading activity of Halozyme Therapeutics Inc. (HALO) gives us an average price of $44.70, while its current price level is 11.44% below from 52-week high level whereas it is 56.92% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $41.62 while that of 200 days or SMA-200 reads an average of $38.95. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.96% during that period while stretching the period over a month that decreases to 3.63%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 77.83 which implies that the stock is in overbought territory.

The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the TD Cowen which initiated the stock as “Outperform” in its note to investors issued on February 29, 2024, recommending a price target of $54 for it. Goldman issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $43 and $45.

Over the week, HALO’s stock price is moving 18.66% up while it is 24.82% when we observe its performance for the past one month. Year-to-date it is 39.18% up and over the past year, the stock is showing an upside performance of 51.38%.

Currently, Halozyme Therapeutics Inc.’s total number of outstanding shares is 126.77M. Company’s return on investment (ROI) stands at 18.99% and return on equity (ROE) at 261.68%. It has a price to earnings ratio (P/E ratio) of 21.28 while having a 10.85 of forward P/E ratio. Stock’s beta reads 1.25. Stock has a price to book (P/B) ratio of 36.79 while price to sale or P/S ratio amounts to 7.59. Its return on asset (ROA) is 18.01% on average.